The high incidence of vascular thromboembolic events (VTE) in advanced urothelial cancer (UC) patients (pts) treated with carboplatin (Cb): Analysis of treatment with gemcitabine (G)/cb (GCb), gcb/bevacizumab (GCbBev), or gemcitabine/cisplatin (GCis).
Christopher Michael Tully
No relevant relationships to disclose
Andrea Borghese Apolo
No relevant relationships to disclose
Emily C. Zabor
No relevant relationships to disclose
Ashley Marie Regazzi
No relevant relationships to disclose
Irina Ostrovnaya
No relevant relationships to disclose
Jonathan E. Rosenberg
No relevant relationships to disclose
Dean F. Bajorin
Consultant or Advisory Role - Bristol-Myers Squibb; Lilly
Honoraria - Lilly